Achieve Life Sciences (STU:SP4P) Cyclically Adjusted FCF per Share: €34.02 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:SP4P Achieve Life Sciences Inc STU:SP4P
39 GF Score
Price €5.45
! 4 Warning Signs
View Full Analysis

What is Achieve Life Sciences Cyclically Adjusted FCF per Share?

Achieve Life Sciences STU:SP4P +1.87% 39 Cyclically Adjusted FCF per Share is €34.02 as of Mar. 2026. GuruFocus rates STU:SP4P with a GF Score™ of 39/100. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Achieve Life Sciences's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.112. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €34.02 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 63.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 54.90% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 35.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Achieve Life Sciences was 63.60% per year. The lowest was -12.80% per year. And the median was 12.50% per year.

As of today (2026-07-15), Achieve Life Sciences's current stock price is €5.45. Achieve Life Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €34.02. Achieve Life Sciences's Cyclically Adjusted Price-to-FCF of today is 0.16.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Achieve Life Sciences was 0.16. The lowest was 0.00. And the median was 0.00.


Achieve Life Sciences  (STU:SP4P) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Achieve Life Sciences's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=5.45/34.02
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Achieve Life Sciences was 0.16. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Achieve Life Sciences Cyclically Adjusted FCF per Share Related Terms


Achieve Life Sciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Achieve Life Sciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achieve Life Sciences Cyclically Adjusted FCF per Share Chart

Achieve Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,461.30 -963.11 -330.00 -123.43 -36.08

Achieve Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.23 -194.12 -123.76 -36.08 34.02

STU:SP4P vs STTK, CRMD, EIKN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Achieve Life Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achieve Life Sciences Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's Cyclically Adjusted Price-to-FCF falls into.


STU:SP4P
39GF Score
Achieve Life Sciences Inc STU:SP4P
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Achieve Life Sciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Achieve Life Sciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.112/330.2130*330.2130
=-0.112

Current CPI (Mar. 2026) = 330.2130.

Achieve Life Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -403.929 241.018 -553.413
201609 -462.214 241.428 -632.193
201612 1,523.714 241.432 2,084.024
201703 -0.714 243.801 -0.967
201706 -1.143 244.955 -1.541
201709 -127.139 246.819 -170.096
201712 -51.017 246.524 -68.336
201803 -29.210 249.554 -38.651
201806 -21.039 251.989 -27.570
201809 -11.256 252.439 -14.724
201812 -9.265 251.233 -12.178
201903 -13.021 254.202 -16.915
201906 -9.462 256.143 -12.198
201909 -6.886 256.759 -8.856
201912 -5.609 256.974 -7.208
202003 -2.611 258.115 -3.340
202006 -1.126 257.797 -1.442
202009 -1.120 260.280 -1.421
202012 -0.334 260.474 -0.423
202103 -0.884 264.877 -1.102
202106 -1.019 271.696 -1.238
202109 -0.782 274.310 -0.941
202112 -0.488 278.802 -0.578
202203 -0.651 287.504 -0.748
202206 -0.818 296.311 -0.912
202209 -1.178 296.808 -1.311
202212 -0.775 296.797 -0.862
202303 -0.433 301.836 -0.474
202306 -0.323 305.109 -0.350
202309 -0.228 307.789 -0.245
202312 -0.189 306.746 -0.203
202403 -0.194 312.332 -0.205
202406 -0.133 314.175 -0.140
202409 -0.272 315.301 -0.285
202412 -0.254 315.605 -0.266
202503 -0.296 319.799 -0.306
202506 -0.227 322.561 -0.232
202509 -0.189 324.800 -0.192
202512 -0.285 324.054 -0.290
202603 -0.112 330.213 -0.112

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €34.02 mean?
Achieve Life Sciences (STU:SP4P) has a Cyclically Adjusted FCF per Share of €34.02 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Achieve Life Sciences and its competitors.
Is Achieve Life Sciences' Cyclically Adjusted FCF per Share too high?
Achieve Life Sciences' current Cyclically Adjusted FCF per Share is €34.02. Overall, Achieve Life Sciences has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Achieve Life Sciences' Cyclically Adjusted FCF per Share compare to STTK and CRMD?
Achieve Life Sciences' Cyclically Adjusted FCF per Share of €34.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Achieve Life Sciences and its competitors. Achieve Life Sciences's current Cyclically Adjusted FCF per Share is €34.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Achieve Life Sciences stock overvalued right now?
Achieve Life Sciences (STU:SP4P) has a current Cyclically Adjusted FCF per Share of €34.02. The current Cyclically Adjusted FCF per Share is €34.02. Achieve Life Sciences' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Achieve Life Sciences (STU:SP4P), the current Cyclically Adjusted FCF per Share is €34.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Achieve Life Sciences Business Description

Other Exchanges ACHV:USASP4P:Germany
Address 22722 29th Drive SE, Suite 100, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
39GF Score

Get the complete analysis for STU:SP4P

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.45
Price